PHOEBUS Trial: an international, randomized, double-blind, multicenter phase IIb study evaluating MaaT033, oral allogeneic fecal microbiotherapy, in patients undergoing allo-HSCT to improve overall survival. SEHH Congress (Spanish only)

Previous PostMaaT033 pour assurer un microbiote intestinal optimal afin d'améliorer la survie des patients recevant une allo-CSH : Essai PHOEBUS
Next PostEvaluation of a new co-cultured Microbiome Ecosystem Therapy candidate (MaaT03X) for clinical testing as adjuvant/neoadjuvant to immune checkpoint inhibitors in solid tumors